There's been a notable change in appetite for Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shares in the week since its yearly report, with the stock down 17% to US$0.44. The statutory results were not great - while revenues of US$18m were in line with expectations,Ekso Bionics Holdings lost US$0.56 a share in the process. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Check out our latest analysis for Ekso Bionics Holdings

Taking into account the latest results, the most recent consensus for Ekso Bionics Holdings from two analysts is for revenues of US$22.0m in 2025. If met, it would imply a substantial 23% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 38% to US$0.32. Before this earnings announcement, the analysts had been modelling revenues of US$23.6m and losses of US$0.23 per share in 2025. So it's pretty clear the analysts have mixed opinions on Ekso Bionics Holdings after this update; revenues were downgraded and per-share losses expected to increase.

The analysts lifted their price target 64% to US$9.00, implicitly signalling that lower earnings per share are not expected to have a longer-term impact on the stock's value.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Ekso Bionics Holdings' past performance and to peers in the same industry. It's clear from the latest estimates that Ekso Bionics Holdings' rate of growth is expected to accelerate meaningfully, with the forecast 23% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 13% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.8% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Ekso Bionics Holdings is expected to grow much faster than its industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Ekso Bionics Holdings. They also downgraded Ekso Bionics Holdings' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2027, which can be seen for free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Ekso Bionics Holdings (at least 1 which is significant) , and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.